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Abstract
Monocyte chemoattractant protein-1 (MCP-1), a CC chemokine (CCL2), has been demonstrated to play important roles in
atherosclerosis and becoming an important therapeutic target for atherosclerosis. The present study was undertaken to test
the hypothesis that local RNAi of MCP-1 by site-specific delivery of adenovirus-mediated small hairpin RNA (shRNA) may
enhance plaque stability and prevent plaque disruption in ApoE2/2 mice. We designed an adenovirus-mediated shRNA
against mouse MCP-1 (rAd5-MCP-1-shRNA). Male apolipoprotein E-knockout (ApoE2/2) mice (n=120) were fed a high-fat
diet and vulnerable plaques were induced by perivascular placement of constrictive collars around the carotid artery,
intraperitoneal injection of lipopolysaccharide and stress stimulation. Mice were randomly divided into RNA interference
(Ad-MCP-1i) group receiving local treatment of rAd5-MCP-1-shRNA suspension, Ad-EGFP group receiving treatment of rAd5-
mediated negative shRNA and mock group receiving treatment of saline. Two weeks after treatment, plaque disruption
rates were significantly lower in the Ad-MCP-1i group than in the Ad-EGFP group (13.3% vs. 60.0%, P=0.01), and local MCP-
1 expression was significantly inhibited in the Ad-MCP-1i group confirmed by immunostaining, qRT-PCR and western blot
(P,0.001). Compared with the Ad-EGFP group, carotid plaques in the Ad-MCP-1i group showed increased levels of collagen
and smooth muscle cells, and decreased levels of lipid and macrophages. The expression of inflammatory cytokines and
activities of matrix metalloproteinases (MMPs) were lower in the Ad-MCP-1i group than in the Ad-EGFP group. In conclusion,
site-specific delivery of adenoviral-mediated shRNA targeting mouse MCP-1 downregulated MCP-1 expression, turned a
vulnerable plaque into a more stable plaque phenotype and prevented plaque disruption. A marked suppression of the
local inflammatory cytokine expression may be the central mechanism involved.
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Introduction
Atherosclerotic plaque disruption has been identified as the
major cause of acute coronary syndrome [1]. A plaque with a large
necrotic core and a thin fibrous cap infiltrated by inflammatory
cells is vulnerable to disruption. Current evidence demonstrated
that inflammation plays a pivotal role in plaque instability and
Inflammatory cell recruitment is mediated by various chemotactic
cytokines or chemokines [2,3]. Inhibition of chemokine activity is
becoming a therapeutic target in clinical trials of inflammatory
disorders [4].
Monocyte chemoattractant protein-1 (MCP-1), a CC chemo-
kine (CCL2), promotes atherosclerosis by recruiting macrophages
and monocytes to the vessel wall. MCP-1 was detected in
atherosclerotic lesions [5–8] and responsible for regulating the
local expression of adhesion molecules, interleukin-1 (IL)-1, IL-6
and tissue factor [9,10]. In recent years, MCP-1 has become an
important therapeutic target for atherosclerosis and three
treatment approaches have been developed in experimental
studies. The first approach involved systemic blocking MCP-1
by injection of an N terminal-deletion mutant of the MCP-1 gene
(7ND) and Inoue S et al first showed that 7ND treatment
attenuated progression of the atherosclerotic lesions in ApoE2/2
mice [11]. Our group first reported that 7ND transfection reversed
plaque progression and prevented vulnerable plaques from
rupture in a rabbit model [12]. However, it is difficult to translate
this approach into clinical application because long-term injection
of 7ND may cause hypersensitivity reaction and systemic
immunosuppression. The second approach used CCR2 receptor
blocker but a recent study found no beneficial effects with this
therapy in a mouse model of atherosclerosis, possibly because the
CCR2 receptor may have other functions beyond the control of
monocyte emigration [13]. The third approach entails local gene
silencing of MCP-1 using RNA interference (RNAi) and if this
technique proves effective and safe, it would be feasible to translate
RNAi into clinical application by combining small interference
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transcription. However, it is still unknown whether local RNA
interference of MCP-1 gene can prevent plaque disruption at an
advanced stage of atherosclerosis, mostly because the complete
gene sequence of MCP-1 in rabbits is unknown and a mouse
model of vulnerable plaque mimic to human counterpart is still
lacking. Recently we have successfully developed a novel animal
model of vulnerable carotid plaque by introducing stress and
lipopolysaccharide (LPS) stimulation to ApoE2/2 mice, which
shared many characteristics of vulnerable plaque in humans [14].
Pathological studies demonstrated that there was a marked
increase in the expression of inflammatory factors in the carotid
plaque in this animal model, and among these factors, MCP-1
exhibited the most significant increase in the level of protein
expression. These observations suggest that inflammation is likely
the central mechanism of plaque instability and MCP-1 might
offer a pivotal target for preventing plaque disruption.
In the present study, we hypothesized that local RNAi of MCP-
1 by site-specific delivery of adenovirus-mediated small hairpin
RNA (shRNA) may enhance plaque stability and prevent plaque
disruption in our established mouse model of vulnerable plaque,




The animal experimental protocol complied with the Animal
Management Rules of the Chinese Ministry of Health (document
No 55, 2001) and was approved by Animal Care Committee of
Shandong University.
Plasmids and Adenovirus Construction
RNAi Target Finder (GenScript Corp., USA) was used to select
the RNAi candidate targets for mouse MCP-1 gene following the
guidelines established by Elbashir [15]. The DNA sequences
coding the shRNA for MCP-1 (gene ID: BC055070, target
sequence 184 to 204) were cloned into the shRNA expression
plasmid Pgenesil-1 (Wuhan GeneSil Biotechnology, Wuhan,
China), a linear double-stranded DNA consisting of the human
U6 promoter. Pgenesil-1-shRNA was cloned into an adenoviral
shuttle vector and joined with the recombinant adenovirus type 5
(rAd5) vector by homologous recombination to construct rAd5-
MCP-1-shRNA. rAd5-mediated negative shRNA, which contains
a nonsense sequence (59-GAC TTC ATA AGG CGC ATG C-39),
served as a control. Both rAd5-MCP-1-shRNA and the negative
control vector encoded the sequences for enhanced green
fluorescent protein (EGFP).
Animal Preparation
One hundred and twenty ApoE2/2 mice (male, 12 weeks old)
were obtained from Peking University (Beijing, China). Mice were
kept on a 12-hr light/12-h dark cycle, with food and water freely
available. All animals were fed a high-fat diet (0.25% cholesterol
and 15% cocoa butter) for 12 weeks. The animal grouping and
time line of the experimental protocol were shown in Figure 1.
Animal Model
In our previous study [14], combined stimulation of mental
stress and lipopolysaccharide (LPS) was used to create a vulnerable
plaque model in ApoE2/2 mice fed with high-fat diet. In the
present study, we applied this animal model to test our research
hypothesis. In brief, carotid atherosclerotic lesions were induced
by placement of a restraint perivascular silica collar (3 mm in
length and 0.3 mm in internal diameter) around the left common
carotid artery [16]. Four weeks after collar placement, mice were
injected intraperitoneally with LPS (1 mg/kg in 0.2 ml phosphate-
buffered saline, Sigma, USA) twice a week for 8 weeks to induce
chronic inflammation. Then, mice were stressed with a 1-h electric
foot-shock (0.5 mA for 5 s every 3 min) and noise stimulation
(110 dB for 5 s every 3 min) by use of a noise generator (DJ-001,
Jianda Technology, China) every day for 4 weeks to induce a
hyperhemodynamic status. The intensity of the electric current
was adjusted to a minimal level to avoid intolerable pain and skin
injury to the mice. To evaluate the effects of stress on
hemodynamics, systolic blood pressure (SBP), diastolic blood
pressure (DBP) and heart rate (HR) were measured at week 8
before stress stimulation, at week 10 before adenovirus transfection
and at week 12 at the end of the experiment, respectively, using a
noninvasive tail-cuff system (Softron BP-98A, Tokyo, Japan).
rAd-MCP1-shRNA Delivery in vivo
Ten weeks after collar placement, all mice were anesthetized
again with intraperitoneal injection of pentobarbital sodium
(40 mg/kg) and the carotid collars were removed. Mice were
randomly divided into three groups for treatment: Ad-MCP-1i
group (n=40), Ad-EGFP group (n=40) and mock group (n=40).
In the Ad-MCP-1i group, 1.25610
9 pfu of rAd5-MCP-1-shRNA
suspension was gently spread around the adventitia of the left
common carotid artery and incubated for 20 min at room
temperature [17]. The Ad-EGFP group and the mock group
underwent the same treatment but with rAd5-mediated negative-
control shRNA (1.25610
9 pfu) and normal saline, respectively.
After gene administration, the skin incision was closed and mice
were allowed to recover. Before and for 3 days after the adenovirus
delivery, mice were free from any stimulation to ensure their
safety.
Biochemical Analysis
Two weeks after adenovirus transfection, mice were euthanized
and weighed, and blood samples were taken from retro-orbital
bleeding. The serum levels of total cholesterol, triglycerides, low-
density lipoprotein cholesterol, and high-density lipoprotein
cholesterol were measured using commercial kits (Roche Diag-
nostics, Indianapolis, IN). The plasma levels of fibrinogen were
measured as previously described [14].
Histology and Immunostaining
One mouse from each group was euthanized three days after
adenovirus transfection and the remaining mice were euthanized
two weeks after transfection. The carotid plaques from 15 mice of
each treatment group were used for histological and immuno-
chemical analyses. The left ventricle was perfused with phosphate-
buffered saline and then with 4% paraformaldehyde under
physiological pressure. The left common carotid artery, heart,
liver and kidney were dissected and fixed in 4% paraformaldehyde
overnight, and then embedded in OCT compound. Serial
cryosections, 6 mm thick, were cut every 50 mm along the carotid
artery. Sections were analyzed for EGFP expression by fluores-
cence microscopy after treatment with 0.5% Chicago Sky Blue
(Sigma, USA) to inhibit the background autofluorescence of the
tissue.
Sections underwent routine staining with hematoxylin and
eosin. Collagen was depicted by Masson’s-trichrome and Sirius-
red staining. Elastin and lipid depositions were identified by
Verhoeff staining and Oil-red O staining, respectively. Perl’s
staining was applied to detect iron deposits, which indicated
plaque hemorrhage. The remaining sections were used for
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ies: anti-monocytes/macrophages (MOMA-2, 1:25, Serotec; UK),
anti-tumor necrosis factor (TNF)-a (1:50, Abcam, UK), anti-
matrix metalloproteinase (MMP)-2 (1:200, Abcam), anti-a-smooth
muscle (SM) actin (1:1000, Sigma), anti-IL-6 (1:400, Abcam), anti-
MMP-9 (1:500, Abcam), anti-MCP-1 (1:50, Abcam) and anti-
MMP-12 antibody (1:500, RayBiotech, USA). After incubation
with the appropriate horseradish peroxidase-conjugated secondary
antibodies (1:100, Zhongshan Biological Technology, China),
sections were incubated with 39,39-diaminobenzidine and coun-
terstained with hematoxylin. To locate the site in the plaque where
MCP-1 expression was reduced by the local delivery of rAd5-
MCP-1-shRNA, sections were immunostained with specific anti-
MCP-1 antibody (1:50, Abcam) for 12 hrs at 4uC and then
incubated with Alex 549-conjugated secondary antibody (1:1000,
Invitrogen). Cell nuclei were counterstained by DAPI (Sigma). The
expression of MCP-1 and GFP in plaques was observed using a
confocal microscope (Zeiss, German). Sections reacted with
nonimmune IgG, secondary antibody only, and no primary and
secondary antibodies were used as negative controls.
Morphologic Analysis
In the present study, plaque disruption was defined as
discontinuity of the fibrous cap, buried fibrous cap, or plaque
hemorrhage [18,19]. Fibrous cap discontinuity implies a structural
defect in the cap, resulting in exposure of the necrotic core to the
blood via the gap in the cap. Buried fibrous caps are indicative of
healed plaque rupture. Plaque hemorrhage may originate either
from the lumen through a ruptured cap or from breakdown of
defective microvessels within the plaque. Plaque disruption was
examined by analysis of sections at 50-mm intervals. For
calculating plaque disruption rate, any ruptured plaque in a given
animal was counted only once no matter how many sections from
one specimen demonstrated evidence of plaque disruption.
Plaque area was calculated by subtracting the patent lumen area
from the area circumscribed by the internal elastic lamina. The
severity of atherosclerotic lesions in each vessel was determined by
analysis of sections at 50-mm intervals and the site of maximal
plaque size was selected for morphologic analysis. The cap
thickness and the cap, core and plaque areas were measured by
use of an automated image analysis system (Image-Pro Plus 5.0,
Media Cybernetics, USA) attached to a color CCD video camera.
Positive staining areas were quantified by computer-assisted color-
gated measurement, and the ratio of the positive staining area to
the plaque area was calculated.
Real-Time RT-PCR
Total RNA was extracted from the carotid arteries (n=12 for
each group) using Trizol reagent (Invitrogen, USA). Reverse
transcription involved use of the M-MLV Kit (Promega, USA)
following the manufacturer’s protocol. The mRNA expression
levels of MCP-1 and alpha 1 subunit of type IV collagen (Col IV-
a1) were quantified by real-time RT-PCR with the SYBR Green
technology. The sequences of primers (59 to 39) were (1) for MCP-
1: CAGCCAGATGCAGTTAACGC (forward) and GCCTACT-
CATTGGGATCATCTTG (reverse); (2) for Col IV-a1:
CTGGCACAAAAGGGACGAG (forward) and ACGTGGCC-
GAGAATTTCACC (reverse). Quantitative values were obtained
from the threshold cycle value. The housekeeping gene b-actin
was used as an internal control. The target bands were verified by
gel electrophoresis. The 2
2DDCT method for comparing relative
expression between treatments in real-time PCR was applied as
described [20].
Western Blot Analysis
Carotid plaques from 12 mice of each group were used for
western blot analysis. Equal amounts of protein (25 ug) obtained
from fresh carotid lesions underwent 10%–15% SDS-PAGE, were
transferred to nitrocellulose membranes and then probed with the
following specific antibodies: anti-MCP-1 antibody (1:200), anti-
collagen IV (1:800, Abcam), anti-p-p65 (1:1000, Cell Signaling
Technology, USA) and anti-T-p65 (1:1000, Cell Signaling
Technology). The membranes were incubated with peroxidase-
labeled secondary antibody (1:10000) at room temperature for
2 hrs and the blots were developed with enhanced chemilumines-
cence (Millipore). The intensities of acquired bands were measured
by computerized image analysis and normalized to that of b-actin.
Zymography
MMP-2 and MMP-9 activities were evaluated by gelatin
zymography. The vessel proteins were mixed with the same
amount of non-reducing sample buffer and resolved by electro-
phoresis on a sodium dodecylsulfate (SDS) 210% polyacrylamide
gels containing gelatin at a concentration of 1 mg/mL. After
electrophoresis, the substrate gels were incubated twice with
Triton-X-100 solution (2.5%) for 30 minutes each at room
Figure 1. The animal grouping and time line of the experimental protocol. LPS, lipopolysaccharide.
doi:10.1371/journal.pone.0033497.g001
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50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 5 mM CaCl2, 0.02%
NaN3, and 0.05% Brij 35 for 24 hours at 37uC. The lysis of the
substrates in the gels was visualized by staining with 2.5%
Coomasie brilliant blue (Sigma). Gelatinolytic activity was
detected as white lysis zones against a blue background.
MMP-12 activity was evaluated by casein zymography. Vessel
proteins were mixed with the same amount of non-reducing
sample buffer and resolved by electrophoresis on a SDS-10%
polyacrylamide gel containing a-casein (Sigma) at a concentration
of 1 mg/ml. Thereafter, gels were incubated in 2.5% (v/v) Triton
X-100 for 30 minutes and soaked for 16 hours in a buffer
containing 10 mM CaCl2 and 100 mM NaCl at 37uC. The gels
were then stained with Coomassie brillant blue G250. Caseinolytic
activity was detected as white lysis zones against a blue
background.
Statistical Analysis
Quantitative values were expressed as mean 6 SEM and
analyzed by unpaired t-test, one-way ANOVA, or repeated
measures ANOVA as appropriate. Post hoc comparisons were
carried out with least significant difference (LSD) test when equal
variances were assumed or with Dunnett test when equal variances
were not assumed. Qualitative data were analyzed by chi-square
test. Correlations were analyzed by linear regression analysis.
SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used for statistical
analysis, and a level of P,0.05 was considered significant.
Results
Hemodynamic and Biochemical Measurements
For each group of mice, SBP, DBP and HR increased
significantly at week 10 and 12, i.e., 2 and 4 weeks after stress
stimulation, compared with the corresponding parameters mea-
sured at week 8 before stress stimulation (all P,0.05, Figure S1A–
S1C). There were no significant differences in SBP, DBP and HR
among the three groups of mice at any of the three time points
(Figure S1A–S1C). Similarly, no significant difference was found
in body weight, serum levels of total cholesterol, triglycerides,
HDL and LDL cholesterol (Table 1), and plasma fibrinogen level
(Figure S1D) among the three groups of mice.
Efficiency of Adenovirus Transfection
The relative staining area of EGFP in the carotid plaques was
46.064.3% and 21.862.7% three days and two weeks after
shRNA delivery, respectively (Figure 2A). In contrast, the relative
staining area of EGFP was only 2.160.4% in the liver and
undetectable in the heart and kidney 3 days after shRNA delivery.
RT-PCR and western blot analyses further demonstrated that the
mRNA and protein expression levels of MCP-1 in the carotid
plaque were significantly lower in the Ad-MCP-1i group than in
the Ad-EGFP group (Figure 2B and 2C). Colocalization of
adenovirus vector and MCP-1 expression by immunostaining
further confirmed that MCP-1 expression was especially reduced
in the GFP-positive lesion in the Ad-MCP-1i group, compared
with the Ad-EGFP group (Figure 2D).
Morphologic Changes of the Carotid Plaque
Consistent with our previous study, carotid plaques in the mock
and Ad-EGFP groups exhibited a high incidence of plaque
disruption including fibrous cap discontinuity (Figure 3A), buried
fibrous cap (Figure 3B) and plaque hemorrhage (Figure 3C). In
contrast, most of the carotid plaques in the Ad-MCP-1i group
showed intact fibrous cap (Figure 3D), and the incidence of plaque
disruption in the Ad-MCP-1i group (13.3%) was significantly
lower than that in the Ad-EGFP group (60.0%, P,0.05) or in the
mock group (66.7%, P,0.05, Table 2). Compared with the Ad-
EGFP group, the Ad-MCP-1i group showed significantly higher
fibrous cap thickness (9.3861.74 mm vs. 6.4461.07 mm; P,0.001,
Figure 3E) and cap to core area ratio (0.0960.02 vs. 0.0660.02;
P=0.001, Figure 3F). The plaque area tended to be lower in the
Ad-MCP-1i group than the Ad-EGFP and mock groups but the
differences did not reach a significant level (P=0.051, Figure 3G).
Composition Changes of the Carotid Plaque
As shown in Figure 4, carotid plaques in the Ad-MCP-1i group
showed a lower content of lipids and macrophages but a higher
content of smooth muscle cells and collagen than those in the Ad-
EGFP group (P,0.05). There was no significant difference in the
expression of collagen IV, a major constituent of the basement
membrane of the carotid artery, among the three groups (Figure
S2A–S2C).
Plaques from the Ad-MCP-1i group exhibited significantly a
lower level of MCP-1 expression than those from the Ad-EGFP
group (P,0.001; Figure 5). The expression levels of inflammatory
cytokines including IL-6 and TNF-a (Figure 5) and matrix
metalloproteinases (MMPs) including MMP-2, MMP-9 and
MMP-12 (Figure 6A) in the carotid plaque were markedly
decreased in the Ad-MCP-1i group as compared with the Ad-
EGFP group. Zymography revealed that the activities of MMP-2,
MMP-9 and MMP-12 in the carotid plaques were significantly
decreased inthe Ad-MCP-1igroup as compared withthe Ad-EGFP
group (Figure 6B). In addition, the expression of p-p65 and the ratio
of p-p65 to T-p65 were significantly decreased in the Ad-MCP-1i
group, as compared with Ad-EGFP group, indicating a suppressed
NF-kB activation in the Ad-MCP-1i group (Figure S2B and S2D).
Correlation between MCP-1 and Other Inflammatory
Markers
The protein expression level of MCP-1 was correlated with the
relative content of macrophages and the protein expression levels
of IL-6, TNF-a, MMP-2, MMP-9 and MMP-12 in the carotid
plaque of the three groups of rabbits based on quantitative analysis
of immunohistochemical staining. The results showed that the
protein expression levels of MCP-1 correlated highly with the
relative content of macrophages (r=0.83, P,0.001) and with the
protein expression levels of IL-6 (r=0.93, P,0.001), TNF-a
(r=0.92, P,0.001), MMP-2 (r=0.80, P,0.001), MMP-9
(r=0.74, P,0.01), and MMP-12 (r=0.89, P,0.001).




Body weight (g) 27.8361.60 28.9761.38 28.1461.74
Total cholesterol (mmol/L) 16.1164.07 17.4764.15 16.2863.91
Triglyceride (mmol/L) 0.5460.17 0.4660.13 0.4960.14
LDL-C (mmol/L) 5.5861.49 5.2261.24 5.5161.16
HDL-C (mmol/L) 1.5360.27 1.4860.29 1.5360.23
Data were mean 6 SEM. LDL-C, low-density lipoprotein cholesterol; HDL-C,
high-density lipoprotein cholesterol.
doi:10.1371/journal.pone.0033497.t001
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The most important finding of the present study was that site-
specific delivery of adenoviral-mediated shRNA targeting mouse
MCP-1 significantly inhibited MCP-1 expression in the vulnerable
carotid plaque of ApoE2/2 mice, leading to a more stable plaque
phenotype with fewer macrophages, less accumulation of lipids,
attenuated expression of inflammatory cytokines and MMPs, more
smooth muscle cells and enriched collagen. These plaque
composition changes resulted in a more than 4-fold decrease in
plaque disruption rate in the RNAi group compared with the
control group. Moreover, there were high correlations between
MCP-1 expression levels and relative content of macrophages or
expression levels of other inflammatory factors in carotid plaques.
To the best of our knowledge, this study was the first to report that
local gene silencing of MCP-1 may enhance plaque stability and
prevent plaque disruption in ApoE2/2 mice.
ApoE2/2 mice have been widely used as an animal model of
atherosclerosis and the murine carotid plaque induced by high-fat
diet feeding and paravascular collar placement has been
recognized as the most reproducible site for studies of advanced
lesions [21]. Recently, we developed a new mouse model of
vulnerable carotid plaque by using combinatorial stress stimulation
and LPS injection and observed a high incidence of plaque
disruption in these mice. The pathophysiological mechanisms
underlying plaque disruption in this animal model involved
Figure 2. Efficiency of adenovirus transfection in ApoE2/2 mice. A, Fluorescence images of the carotid plaques before (left) and three days
(middle) and two weeks (right) after adenovirus transfection in the Ad-MCP-1i group. Vessel sections were first treated with SkyBlue 6B to eliminate
background autofluorescence of the plaque. Bar=100 mm; B, mRNA expression of MCP-1 in three groups of mice. ***P,0.001 vs. Ad-EGFP group; C,
protein expression of MCP-1 by western blot analysis in three groups of mice. ***P,0.001 vs. Ad-EGFP group; D, Colocalization of the MCP-1 (red) and
GFP (green) expression in the carotid plaques in three groups of mice. DAPI (blue) indicated nuclei.
doi:10.1371/journal.pone.0033497.g002
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inflammatory processes [14]. In the present study, the plaque
disruption rate was 66.7% and 60.0% in the mock group and the
Ad-EGFP group, respectively, a finding consistent with our
previous report [14].
Among a number of chemokines implicated in atherosclerosis,
MCP-1 (i.e., CCL2) is the key chemokine responsible for
accumulation of inflammatory cells in atherosclerotic lesions after
interaction with its receptor CCR2. This MCP-1–CCR2 interac-
tion leads to activation of G-protein-coupled receptors and then
diapedesis of monocytes between endothelial cells [22] Previous
studies showed that enhanced expression of MCP-1 gene
remarkably promoted whereas its deletion significantly attenuated
atherosclerotic lesions [23–25]. Aortic atherosclerotic lesions from
LDL-receptor/MCP-1 double-knockout mice showed less lipid
deposition and fewer macrophages [26], which suggests that
MCP-1 is related to plaque instability. In addition, MCP-1
induced tissue-factor expression in smooth muscle cells and T-
helper 1 (Th1) cells [10], suggesting that MCP-1 has a
procoagulant function. Based on available experimental evidence,
it is logical to speculate that MCP-1 offers a promising target for
the treatment of vulnerable plaques.
The RNAi method selectively and efficiently silences mRNA for
a wide range of proteins [15] and has been used in experimental
studies for treating or preventing several diseases [27–29]. Two of
the most important considerations for developing RNAi as a
feasible therapy are first, devising efficient mechanisms for delivery
of small-interfering RNA (siRNA) to the target cells in vivo, and
second, avoiding nonspecific or off-target effects of the siRNA.
However, with the systemic delivery method, biodistribution of
radiolabeled siRNA in mice demonstrated that most of the siRNA
accumulated in the liver and kidneys [30]. Lewis et al showed that
systemic coinjection of luciferase reporter plasmids with siRNA
luciferase resulted in strong inhibition of luciferase activity not only
in the liver but also in kidney, spleen, lung, and pancreas of
postnatal mice, which suggests that in mammals, siRNA can be
delivered effectively into many organs after systemic application
[31]. In order to achieve high-titer rAd5-shRNA in the carotid
plaque, we used a site-specific delivery method by spreading the
adenovirus suspension around the adventitia of the carotid artery,
which was incubated for 20 min at room temperature. Previous
studies have demonstrated that site-directed silencing of gene
expression is effective and efficient. Furthermore, the inhibitory
effects of MCP-1 lasted for two weeks. To assess the nonspecific or
Figure 3. Morphological characteristics of the carotid plaque in three groups of ApoE2/2 mice. A, Discontinuity of fibrous cap in the Ad-
EGFP group. Arrows indicated the structural defects in the fibrous cap; B, Buried fibrous cap in the Ad-EGFP group. Arrows indicated a layer of fibrous
cap within a plaque. C, Plaque hemorrhage in the Ad-EGFP group. Arrows indicated erythrocytes within the plaque; D, An intact carotid plaque in the
Ad-MCP-1i group; E–G, quantitative analysis of the fibrous cap thickness (E), the cap to core area ratio (F) and the plaque area (G) in three groups of
mice. ** P,0.01, *** P,0.001, vs. Ad-EGFP group.
doi:10.1371/journal.pone.0033497.g003
Table 2. Incidence of plaque disruption in three groups of
mice.
Plaque complications Mock Ad-EGFP Ad-MCP-1i
(n=15) (n=15) (n=15)
Fibrous cap discontinuity (n) 5 4 1
Buried fibrous cap (n) 4 3 1
Plaque hemorrhage (n) 1 2 0
Total disruption (n, %) 10 (66.7%) 9 (60.0%) 2 (13.3%)*
*P,0.05, vs. Ad-EGFP or Mock group.
doi:10.1371/journal.pone.0033497.t002
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EGFP expression in the heart, liver and kidney and found little
expression of EGFP in these organs, which suggested that the
siRNA site-specific delivery method was safe and did not affect
primary organs other than the targeted vessels.
In our previous study, we found that dominant-negative
mutation of MCP-1 (plRES-EGFP-7ND) attenuated atheroscle-
rotic lesion progression and prevented vulnerable aortic plaques
from rupture in a rabbit model [12]. In the present study, we
obtained similar results in a mouse model of vulnerable plaque and
found that Ad-MCP-1-shRNA treatment reduced the MCP-1
gene expression to a greater extension (73.9%) than plRES-EGFP-
7ND treatment (60.5%) [12]. Recent studies found that siRNA
treatment was as effective as antisense oligonucleotide treatment in
both in vitro and in vivo experiments [32,33]. Moreover, siRNAs
treatment requires no chemical modifications, which results in a
high safety profile. Conversely, long-term injection of therapeutic
antibodies or recombinant protein infusions may induce systemic
immnosuppression or undesirable immune responses against the
foreign protein by the host.
Figure 4. Carotid plaque compositions in three groups of mice. A, Representative Sirius-red staining of collagen, Oil-red O staining of lipids,
MOMA-2 immunostaining of macrophages and a-SMC-actin immunostaining in three groups of mice; (B) Quantification of staining results in three
groups of mice. * P,0.05, ** P,0.01, ***P,0.001 vs. Ad-EGFP group.
doi:10.1371/journal.pone.0033497.g004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33497In this study, local gene silencing of MCP-1 resulted in 70%
reduction in MCP-1 protein expression in the carotid plaque,
leading to a marked decrease in the local expression of inflammatory
cytokines including IL-6, TNF-a, MMP-2, MMP-9 and MMP-12.
These cytokine changes translated into a stable plaque phenotype
manifested as decreased macrophages and lipids, and increased
smooth musclecells,collagen and fibrouscap thickness inthe carotid
plaque. All these changes resulted in a 78% reduction in plaque
disruption rate from 60% in the Ad-MCP-1i group to 13% in the
Ad-EGFP group, implying that local gene silencing of MCP-1 may
effectively prevent disruption of the vulnerable carotid plaque in
most ApoE2/2 mice. It should be noted that local gene silencing of
MCP-1 produced no impact on serum lipid levels and thus the
plaque-stabilizing effect of this gene therapy were lipid-independent.
These results confirmed our speculation that inflammation is the
central mechanism of plaque instability and MCP-1 offers a pivotal
target for preventing plaque disruption.
There were several limitations in this study. First, although the
plaque-stabilizing effect of MCP-1 gene silencing was encouraging
and suppression of inflammatory cytokines was probably the major
underlying mechanisms, the detailed signaling pathways were not
explored and needs further investigation. Second, different from
our previous study in a rabbit model of vulnerable plaque where
the plaque burden was significantly reduced by 7ND treatment,
local gene silencing of MCP-1 in the present study resulted in an
only insignificant reduction in the carotid plaque area. Different
animal models and treatment approaches may explain this
outcome difference.
In conclusion, in the mouse model of vulnerable plaque, site-
specific delivery of adenoviral-mediated shRNA targeting mouse
MCP-1 downregulated MCP-1 expression, turned a vulnerable
plaque into a more stable plaque phenotype and prevented plaque
disruption. The central mechanism may involve a marked
decrease in the local expression of inflammatory cytokines. Thus,
Figure 5. Protein expression of inflammatory cytokines in three groups of mice. A, representative immunostaining of MCP-1, IL-6 and TNF-a in
three groups ofmice; B, quantitative analysis of MCP-1, IL-6 and TNF-a p r o t e i ne x p r e s s i o ni nt h r e eg r o u p so fm i c e .*P,0.01,** P,0.001 vs. Ad-EGFP group.
doi:10.1371/journal.pone.0033497.g005
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33497local gene silencing of MCP-1 may provide an effective approach
to the treatment of vulnerable atherosclerotic plaques.
Supporting Information
Figure S1 Hemodynamic parameters and plasma fi-
brinogen levels in three groups of mice. A–C, systolic blood
pressure (A), diastolic blood pressure (B) and heart rate (C) in three
groups of mice at week 8 (before stress), week 10 (two weeks after
stress), week 12 (four weeks after stress). *P,0.05 vs. week 8 in the
mock group;
#P,0.05 vs. week 8 in the Ad-EGFP group,
{P,0.05, vs. week 8 in the Ad-MCP-1i group; D, plasma
fibrinogen levels in three groups of mice.
(TIF)
Figure S2 Expression of collagen IV and activation of
NF kappa B in three groups of mice. A, mRNA expression
of alpha 1 subunit of type IV collagen (Col IV-a1) in three groups
of mice; B, Western blot analysis showing protein expression of
collagen IV, phospho-NF-kB-p65 (p-p65) and total NF-kB-p65 (T-
p65) in three groups of mice. C, quantitative analysis of the
collagen IV protein expression in three groups of mice. D,
quantitative analysis of the protein expression of p-p65, T-p65 and
the ratio of p-p65 to T-p65 (p-p65/T-p65) in three groups of mice.
*P,0.05, **P,0.01, vs. Ad-EGFP group.
(TIF)
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